Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Phase 2

Completed

• Conditions: Type 2 Diabetes Mellitus; Diabetes Mellitus, Type II

• Registration Number: NCT00189774
• Lead Sponsor: Astellas Pharma Inc

Brief Summary

The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-19
• Status Verified: 2008-03
• Last Update Submitted: 2008-03-11
• Last Update Posted: 2008-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Type 2 diabetes mellitus under the treatment with pioglitazone

Exclusion Criteria

• Patients who cannot follow the diet therapy and/or exercise therapy
• Type 1 diabetes mellitus

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL